Prelude Therapeutics Inc

Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.

PRLD | NDAQ

Overview

Corporate Details

ISIN(s):: US74065P1012
LEI:
Country:: United States of America
Address:: 175 INNOVATION BOULEVARD, 19805 WILMINGTON
Website:: https://preludetx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet medical needs. The company's pipeline features multiple novel drug candidates, including first-in-class, highly selective SMARCA2 and KAT6A protein degraders. Leveraging its expertise in targeted protein degradation, Prelude Therapeutics also develops next-generation degrader antibody conjugates (ADCs) through partnerships. The company employs a science-driven, target-agnostic approach to create therapies that precisely address the drivers of cancer cell growth and mechanisms of resistance, aiming to advance transformational treatments into clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prelude Therapeutics Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prelude Therapeutics Inc

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Prelude Therapeutics Inc via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Active Biotech Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.	Sweden	ACTI
ACTUATE THERAPEUTICS, INC. Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.	United States of America	ACTU
AcuCort AB Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.	Sweden	ACUC
Acurx Pharmaceuticals, Inc. Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.	United States of America	ACXP
Adagene Inc. Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.	United States of America	ADAG
Adaptimmune Therapeutics PLC Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.	United States of America	ADAP
ADBIOTECH Co.,Ltd. Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.	South Korea	179530
ADC Therapeutics SA Develops targeted antibody-drug conjugates for hematological and solid tumors.	United States of America	ADCT
Addex Therapeutics Ltd. Developing novel oral allosteric modulators to treat neurological disorders.	United States of America	ADXN
ADIAL PHARMACEUTICALS, INC. Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.	United States of America	ADIL